Yaowen Gu is a computational chemistry researcher at New York University, working on artificial intelligence for drug discovery, including binding affinity prediction, virtual screening, and antibody developability. Trained in medical informatics at Peking Union Medical College and in biomedical sciences at Peking University, Yaowen has held research positions at Eli Lilly, SILEXON, and XtalPi. Author of over 20 peer-reviewed publications. Yaowen reviews for more than 20 journals, serves on the program committees of ICLR, ICML, and AAAI.